Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of British Columbia
$60,000.00
Optimizing triple negative breast cancer therapy based on immune cell morphology
EF 2021-22
Résumé
Women diagnosed with triple negative breast cancer face an aggressive, life-threatening disease. Intense chemotherapy remains part of their standard care. However, new evidence suggests that at least some of these breast cancers are cured by surgery and radiation alone. We propose to apply a cost-effective approach using digital pathology on existing microscope slides from completed randomized trials to develop means to identify which women may not need standard chemotherapy. Our first aim will assess tumor killing immune cells (lymphocytes) using a recently validated image analysis method. This information will be integrated with clinical data to develop a risk tool we will apply on two Danish breast cancer trials, testing whether this identifies women with excellent outcomes despite no chemotherapy. For the second aim, we will build on our own most recent genomic findings showing that tumor promoting immune cells (mast cells) predict which women benefit most from an alternative chemotherapy drug (capecitabine). We propose to develop a novel image analysis method to identify these distinct cells on microscope slides, confirm this predicts drug benefit on a Spanish clinical trial, then validate our findings on a Finnish trial. If either aim is successful, this project would lead to inexpensive tests, applicable worldwide, that optimize outcomes for women with triple negative breast cancers while avoiding unwarranted costs and toxicities.
Programme
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
468140
Name
Nielsen Torsten O
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Optimizing triple negative breast cancer therapy based on immune cell morphology
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer; Imaging Technologies; Targets And Biomarkers; Translational Research
Abstract
Women diagnosed with triple negative breast cancer face an aggressive, life-threatening disease. Intense chemotherapy remains part of their standard care. However, new evidence suggests that at least some of these breast cancers are cured by surgery and radiation alone. We propose to apply a cost-effective approach using digital pathology on existing microscope slides from completed randomized trials to develop means to identify which women may not need standard chemotherapy. Our first aim will assess tumor killing immune cells (lymphocytes) using a recently validated image analysis method. This information will be integrated with clinical data to develop a risk tool we will apply on two Danish breast cancer trials, testing whether this identifies women with excellent outcomes despite no chemotherapy. For the second aim, we will build on our own most recent genomic findings showing that tumor promoting immune cells (mast cells) predict which women benefit most from an alternative chemotherapy drug (capecitabine). We propose to develop a novel image analysis method to identify these distinct cells on microscope slides, confirm this predicts drug benefit on a Spanish clinical trial, then validate our findings on a Finnish trial. If either aim is successful, this project would lead to inexpensive tests, applicable worldwide, that optimize outcomes for women with triple negative breast cancers while avoiding unwarranted costs and toxicities.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Nielsen, Torsten O
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~